
## Lauren A Chang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3969683/publications.pdf Version: 2024-02-01



LAUDEN & CHANC

#	Article	IF	CITATIONS
1	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603, 687-692.	13.7	475
2	Recurrent respiratory syncytial virus infection in a CD14 deficient patient. Journal of Infectious Diseases, 2022, , .	1.9	5
3	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. Science Translational Medicine, 2022, 14, .	5.8	7
4	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science, 2021, 373, .	6.0	174
5	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
6	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 1111-1120.	5.2	38
7	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
8	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
9	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Reports, 2020, 33, 108322.	2.9	59
10	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936
11	A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.	6.0	207
12	Epitope-Specific Serological Assays for RSV: Conformation Matters. Vaccines, 2019, 7, 23.	2.1	26